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Abstract
Background: Germline DNA damage repair gene mutation (gDDRm) is found in >10% of metastatic
prostate cancer (mPC). Their prognostic and predictive impact relating to standard therapies is unclear.
Objective: To determine whether gDDRm status impacts beneﬁt from established therapies in mPC.
Design, setting, and participants: This is a retrospective, international, observational study. Medical
records were reviewed for 390 mPC patients with known gDDRm status. All 372 patients from Royal
Marsden (UK), Weill-Cornell (NY), and University of Washington (WA) were previously included in a
prevalence study (Pritchard, NEJM 2016); the remaining 18 were gBRCA1/2m carriers, from the kConFab
consortium, Australia.
Outcome measurements and statistical analysis: Response rate (RR), progression-free survival (PFS),
and overall survival (OS) data were collected. To account for potential differences between cohorts, a
mixed-effect model (Weibull distribution) with random intercept per cohort was used.
Results and limitations: The gDDRmstatuswas known for all 390patients (60 carriers of gDDRm [gDDRm
+], including 37 gBRCA2m, and 330 cases not found to carry gDDRm [gDDRm–]); 74% and 69%were treated
with docetaxel and abiraterone/enzalutamide, respectively, and 36% received PARP inhibitors (PARPi) and/
orplatinum.MedianOSfromcastration resistancewassimilaramonggroups(3.2vs [1_TD$DIFF]3.0yr,p = 0.73).Median
docetaxel PFS for gDDRm+ (6.8mo)was not signiﬁcantly different from that for gDDRm– (5.1mo), and RRs
were similar (gDDRm+ = 61%; gDDRm– = 54%). Therewere no signiﬁcant differences inmedian PFS and RR
on ﬁrst-line abiraterone/enzalutamide (gDDRm+ = 8.3 mo, gDDRm– = 8.3 mo; gDDRm+ = 46%, gDDRm–
= 56%). Interaction test for PARPi/platinumandgDDRm+resulted inanOSadjustedhazard ratioof 0.59 (95%
conﬁdence interval 0.28–1.25; p = 0.17). Results are limited by the retrospective nature of the analysis.
Conclusions: mPC patients with gDDRm appeared to beneﬁt from standard therapies similarly to the
overall population; prospective studies are ongoing to investigate the impact of PARPi/platinum.
Patient summary: Patients with inherited DNA repair mutations beneﬁt from standard therapies
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Inherited mutations in DNA damage repair (DDR) genes
associate with an increased risk of developing prostate,
breast, ovarian, and other cancers [1,2]. We previously de-
scribed enrichment of such mutations in metastatic prostate
cancer (mPC), with 11.8% of these men harbouring germline
DNA damage repair gene mutation (gDDRm) [3]. Mutations
in BRCA2weremost prevalent (5.3%), with these data leading
to a change in National Comprehensive Cancer Network
(NCCN) guidelines, now recommending germline testing for
all men with mPC [4]. Studies in mPC as well as in other
diseases support tailored therapeutic approaches for this
molecularly defined subset of patients [5–8].
Characterisation of the genomic landscape of prostate
cancer has led to the identification of clinically actionable
molecular alterations [9,10]. This renders an opportunity for
a new classification of this common disease, beyond
traditional anatomical and histological considerations,
based on the prognostic and predictive significance of
some of these alterations for treatment stratification.
Prior studies stated the role of germline BRCA2mutations
are an independent poor prognostic factor for localised
prostate cancer, associated with a more aggressive pheno-
type, increased rates of developing metastatic disease, and
shorter survival from the disease [11,12]. However, when
focusing onpatientswithmPC, the prognostic andpredictive
roles of gDDRm are unclear. Prior case series have reported
conflicting data with regard to the relative benefit derived
for patients carrying gDDRm from standard of care ther-
apies (taxanes, abiraterone acetate, enzalutamide) [13–15].
Herein, we retrospectively reviewed the clinical outcome
of mPC patients with and without gDDRm. We included
372 patients from three institutions enrolled in a previously
published prevalence study of gDDRm (Royal Marsden, UK;
Weill-Cornell, NY; University of Washington, WA); in order
to increase the number of gDDRm carriers in this analysis,
we included an additional cohort of 18 known gBRCA1/2m
carriers withmPC from the kConFab consortium (Australia).2. Patients and methods
All patients included had previously been tested for gDDRm. Germline
mutations were called based on a panel of 20 genes summarised in
Supplementary Table 1. For all the 372 cases from the three UK and US
sites, these data had been published in a prior report, including
sequencing and bioinformatics methodology [3]. In the original study,
patients were not selected on the basis of family history, age, or any
knowledge of genetic background. The remaining 18 patients were an
independent cohort of known germline BRCA1/2 germline mutation
carriers from Australia. Patient medical records were retrospectively
reviewed, and patients had received treatment according to local
guidelines. Baseline characteristics (demographic characteristics, age,
Gleason score, prostate-speciﬁc antigen [PSA] and presence ofmetastatic
disease at diagnosis, treatment exposure, and survival data) were
collected. Response data (deﬁned as a 50% PSA fall from baseline and/or
radiological response according to RECIST) and progression-free survival
(PFS; deﬁned as the time from start of a treatment to RECIST/PSA
progression or start of a new therapy for clinical progression) for
abiraterone, enzalutamide, and docetaxel were annotated.To account for potential differences between the cohorts, a mixed-
effect parametric survival model (Weibull distribution) with random
intercept per cohort was used to study correlations with clinical
outcome. Multivariate analyses adjusted for age, Gleason score,
metastatic disease at diagnosis, and prior radical treatment at diagnosis
(either radical prostatectomy or radiotherapy). Fisher's exact test was
used to study response rates to each therapy. A test for interaction was
pursued for an exploratory subgroup analysis assessing the impact of
PARP inhibitors (PARPi) and/or platinum therapy on patient outcome.
Kaplan–Meier curves were used to represent time to event data.
3. Results
3.1. Baseline characteristics and treatment exposure
Clinical data were available for 390 patients including
330 not found to carry gDDRm (gDDRm–) and 60 cases with
presence of gDDRm (gDDRm+). The distribution of genes
mutated per case within the gDDRm+ group was as follows:
BRCA2: 37; ATM: seven; CHEK2: four; BRCA1, PALB2, RAD51D:
two each; others: seven (one patient had both ATM and
CHEK2 mutations; Supplementary Tables 2 and 3). There
were no significant differences in baseline characteristics
based on gDDRm status (Table 1), including age at diagnosis
(median of 62.6 vs 64.9 yr for gDDRm+ vs gDDRm–). Overall,
74% and 69% of patients received, respectively, docetaxel
and novel androgen receptor signalling inhibitors (ARSIs:
abiraterone acetate, enzalutamide) for metastatic castra-
tion-resistant prostate cancer (mCRPC). Based on the cross
resistance demonstrated between abiraterone acetate and
enzalutamide, in this analysis we considered only the first
exposure to either abiraterone acetate or enzalutamide. Of
note, 28/60 (47%) gDDRm+ and 113/330 (34%) gDDRm–
patients also received treatment with PARPi and/or plati-
num chemotherapy, treatments that are not currently
routinely used for prostate cancer care, reflecting the
research focus of the involved academic groups.
3.2. Prognosis of patients with gDDRm
Overall survival (OS) was similar in the two subgroups, with
296 death events (75% of the study population), median OS
from castration resistance was 3.0 yr for gDDRm+ (inter-
quartile range [IQR] 2.4–5.6), 3.0 yr for gBRCA2+ (IQR 2.5–
5.4), and 3.2 yr for gDDRm– (IQR 1.7–5.5; log-rank test
p = 0.73). Inmultivariate analysis, age at diagnosis (per 10 yr
older, adjusted hazard ratio [aHR] 1.45, 95% confidence
interval [CI] 1.21–1.73; p < 0.001), and Gleason score 8
(aHR 1.54, 95% CI 1.16–2.04; p = 0.003), but not germline
mutations (aHR 0.93, 95% CI 0.63–1.37; p = 0.72) were
associatedwithworse survival.When looking specifically at
the impact of germline BRCA2 mutations, these were also
not associated with a significantly different prognosis (aHR
0.83, 95% CI 0.50–1.36, p = 0.45; Table 2 and Fig. 1).
3.3. gDDRm and docetaxel
On docetaxel chemotherapy, gDDRm did not associate with
significantly different PFS (HR 0.86, 95% CI 0.61–1.20,
p = 0.37); similar results were observed when evaluating
Table 2 – Overall survival from castration resistance and
progression-free survival to standard therapies
aHR (MVA) 95% CI p value
OS from castration resistance
Any gDDRm+ 0.93 0.63–1.37 0.72
Age at diagnosis (per 10 yr) 1.45 1.22–1.73 <0.001
Gleason 8–10 1.54 1.16–2.04 0.003
Metastatic disease 1.22 0.84–1.75 0.30
Radical treatment 1.50 1.03–2.18 0.03
HR 95% CI p value
PFS docetaxel
Any gDDRm + 0.86 0.61–1.20 0.37
Only gBRCA2m+ 0.96 0.64–1.43 0.83
PFS ﬁrst line of ARS therapy
Any gDDRm + 0.96 0.69–1.35 0.83
Only gBRCA2m+ 1.10 0.72–1.67 0.67
aHR = adjusted hazard ratio; ARS = androgen receptor signal;
CI = conﬁdence interval; gDDRm = germline DNA damage repair gene
mutation; MVA = multivariate analysis; PSA = prostate-speciﬁc antigen.
Results from a mixed-effect survival model (Weibull distribution) with
random intercept per cohort.
Table 1 – Baseline characteristics of the study population (n = 390)
Patients with any germline
mutation (n = 60)
Patients without germline
mutation (n = 330)
p value a
N % N %
Gleason score
5–7 15 28.9 105 37.5 0.27
8–10 37 71.2 175 62.5
Metastatic disease at diagnosis
No 34 58.6 173 53.7 0.57
Yes 24 41.4 149 46.3
Received radical treatment
No 22 36.7 140 42.4 0.48
Yes 38 58.5 190 57.6
Docetaxel
No 16 26.7 88 26.7 1.00
Yes 44 73.3 242 73.3
Abiraterone and/or enzalutamide
No 18 30 101 30.6 1.00
Yes 42 70 229 69.4
PARPi and/or platinum
No 32 53.3 217 65.8 0.08
Yes 28 46.7 113 34.2
Radium-223
No 52 86.7 296 90.2 0.37
Yes 8 13.3 32 9.8
Median Q1–Q3 Median Q1–Q3 p value b
Age at diagnosis (yr) 62.6 55.3–66.2 62.4 57.7–68.5 0.24
PSA (ng/dl) 17.2 7.7–109.6 33.0 9.8–148.3 0.34
PARPi = PARP inhibitors; PSA = prostate-speciﬁc antigen.
a Fisher's exact test.
b Wilcoxon rank sum test.
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0.64–1.43, p = 0.83). Kaplan–Meier curves for PFS on
docetaxel are shown in Figure 2. Response rate to docetaxel
was 61% and 54% for gDDR+ and gDDR– patients,
respectively (Fisher's exact p = 0.48, Supplementary Ta-
ble 4); this resulted in an odds ratio of response to docetaxel
of 1.33 (95% CI 0.66–2.69; p = 0.43) for patients carrying
gDDRm compared with gDDRm– patients.
3.4. gDDRm and ARSIs (abiraterone, enzalutamide)
PFS on first ARSI (either abiraterone or enzalutamide) for
mCRPC was not significantly different for patients with or
without gDDRm (HR 0.93, 95% CI 0.65–1.32, p = 0.67), with
similar median PFS for gDDRm+ (8.3 mo) and gDDRm–
(8.3 mo; Fig. 2). Patients with BRCA2 mutations also had
similar PFS to the overall population (HR 1.09, 95% CI 0.72–
1.67, p = 0.66). Response rates to the first ARSI were 46% and
56% for gDDRm+ and gDDRm– patients, respectively (Fisher's
exact p = 0.28, Supplementary Table 4), resulting in a
nonsignificant trend towards a lower chance of response
for gDDRm+ (odds ratio 0.65, 95% CI 0.32–1.32, p = 0.23).
3.5. PARPi and platinum in patients with gDDRm
In this cohort, 141 (36%) patients had received PARPi and/or
platinum chemotherapy, including 28/60 (47%) gDDRm+
cases. We explored the potential interaction of thesetreatments and gDDRm on survival from castration resis-
tance in this cohort.
There was no statistically significant impact from PARPi/
platinum on OS for the overall population (aHR 0.97, 95% CI
0.73–1.31; p = 0.88). The hazard of death based on the
presence of gDDR mutations once adjusted for exposure to
[(Fig._1)TD$FIG]
Fig. 1 – Kaplan–Meier curves for survival from date of castration
resistance and from initial diagnosis based on the presence of gDDRm
and specifically for gBRCA2m carriers. CRPC = castration-resistant
prostate cancer; gDDRm = germline DNA damage repair gene mutation;
IQR = interquartile range.
EU RO P E AN U RO LOGY 73 ( 2 018 ) 6 8 7 – 6 9 3690PARPi/platinum indicated no statistically significant differ-
ence in risk of death (aHR 1.23; 95% CI 0.73–2.07; p = 0.44).
An interaction test between gDDRm+ and PARPi/plati-
num therapy revealed an aHR of 0.59 (95% CI 0.28–1.25;
p = 0.17). These data suggest that the association of gDDRm
status and survival could have been impacted by the
exposure to PARPi/platinum. Nevertheless, with this size of
the gDDRm+ subgroup, no statistically significant differ-
ences were observed in this cohort and the null hypothesis
could not be excluded. Survival curves illustrating the
impact of PARPi/platinum by gDDRm status are shown in
Figure 3.
4. Discussion
In this study, we retrospectively reviewed clinical outcome
of lethal prostate cancer patients according to their gDDRm
status [3]. Overall, we did not observe significant differences
in response rate and PFS from docetaxel and ARSIs based on
gDDRm status, suggesting that gDDRm+ carriers derivebenefit from these therapies similarly to the overall
population. These data are of major interest to the clinical
community at this time in view of changes in NCCN
guidelines in 2018 recommending germline testing for all
men suffering from mPC [4].
Prior analyses interrogating this question have reported
conflicting results. A recent retrospective study including
319 patients (22 gDDRm+, 16 being germline BRCA2
mutation carriers) reported shorter OS and worse outcome
from abiraterone/enzalutamide treatment, but not from
docetaxel formCRPC patientswith gDDRm [13]. Preliminary
results of a prospective clinical trial of abiraterone and the
PARP inhibitor veliparib suggested conversely that prostate
cancer patients with DDR defects (here including germline
and somatic alterations) may actually be more likely to
respond to abiraterone acetate therapy [16]. Differences in
the baseline characteristics, genes included in each analysis,
and distribution and prevalence of mutations between
study populations may have accounted for these differ-
ences. The retrospective nature of ours and other studies is a
significant limitation, and prospective validation is required
in ongoing studies [15]. Data from breast cancer studies also
suggest that patients with germline BRCA1/2 mutations
derive significant benefit from taxane-based chemotherapy
[17].
A notable distinction of our patient cohort was the
substantial proportion of patients treated with PARP
inhibitors and/or platinum chemotherapy, which are not
part of the standard of care for prostate cancer. This has to
be taken into account when comparing the survival analysis
in this study to others, since the introduction of these
treatments may have impacted outcome. The use of such
therapies should not, however, have impacted response
data to the specific standard therapies presented here, since
these were largely administered prior to the PARP inhibitor
or platinum therapy. We observed a trend towards
prolonged OS in gDDRm+ patients receiving PARPi/plati-
num. This interaction was not, however, statistically
significant in this small gDDRm+ cohort, and may be a
chance finding or have been impacted by other unrecog-
nised confounding factors [7,8].
Another limitation of our study is the focus on germline,
to the exclusion of somatic only, mutations [9,18,19]. It is
estimated that 20–25% mPC have somatic inactivation of a
DNA repair gene, but just less than half of these carry a
germline mutation. Hence, it is likely that a substantial
proportion of our cases in the gDDRm– group harboured
somatic DDR defects and that some but not all the gDDRm+
cases would have had somatic inactivation of the second
allele.Moreover, the lack of somatic DNAdata for this cohort
also prevented us from analysing the impact of other
concurrent genomic events influencing prostate cancer
progression, such as AR, TP53, or RB1 aberrations. Studies
assessing clinical outcome to specific therapies incorporat-
ing somatic genomic data are ongoing and will be
fundamental to shape precision medicine strategies in
mCRPC and complement ongoing clinical trials of DNA
repair targeting agents in CRPC. These studies and
prospective clinical trials will also need to control for other
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tive study.
5. Conclusions
The data presented here suggest that mPC patients with
inherited mutations in DDR genes, including those with
BRCA2 mutations, can derive similar benefit from standard
of care therapies in terms of both response rate and PFS.
Based on the limitations described, we acknowledge that
this study may not be sufficient to fully inform clinical
decisions; in view of the discrepancies identified among
different retrospective analyses, prospective studies are
now needed evaluating the impact of germline DNA repair
mutations in advanced prostate cancer, beyond their clear
importance to prompt family cascade counselling. Never-
theless, our overall data indicate that detection of gDDRm
should not preclude mPC patients from receiving taxanes,
abiraterone, and enzalutamide as standards of care. Pivotal
clinical trials of PARPi are ongoing for prostate cancer
sufferers with germline and somatic DDRm, and may offer
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